A review of nuclear neurology 

Many people are living longer, but not all are healthy. How can molecular medicine help to diagnose the cognitive impairments that come with age? 

Takeshi Shimizu
Published on June 1, 2021

Population aging has transformed many aspects of society throughout our world. Senior citizens are increasingly acknowledged as important contributors to the community, and developments in social infrastructure facilitate their continued engagement. In addition, their improved levels of activity, productivity, and socioeconomic status affect society and healthcare demands in unexpected ways. 

Objective evidence from nuclear medicine 

Learn more about nuclear medicine

Jun Hatazawa, MD, PhD, currently serves as chief executive director of the Japan Radioisotope Association

Evaluating blood flow 

Molecular imaging for amyloid scans 

Hiroshi Matsuda, MD, PhD, is the current director of the Cyclotron and Drug Discovery Research Center at the Southern Tohoku Research Institute for Neuroscience.

Just the beginning 

By Takeshi Shimizu

Takeshi Shimizu, PhD, is a molecular imaging clinical marketing specialist at Siemens Healthineers. He holds a PhD in biochemistry, microbiology, and molecular biology, and worked as a molecular imaging collaboration scientist for Siemens Healthineers in Japan for 10 years prior to assuming his current role.